Peptinov

Peptinov is a 13-people clinical-stage biotech company based at the Cochin Hospital in Paris, developing an innovative active immunotherapy approach targeting self proteins to treat chronic inflammatory diseases.

Peptinov's therapies are mobilising the patient's own antibodies to modulate the effects of proteins whose overproduction is at the root of pathologies: to do this it has  

set up a drug candidate development platform enabling the induction of antibodies against the targeted proteins in patients. 
 

Its most advanced product targets the inflammatory protein IL-6, involved in chronic low-grade inflammation, the cause and risk factor of multiple inflammatory diseases and pathologies.

Following a successful phase 1 clinical trial in knee osteoarthritis patients (excellent tolerability, induction of anti-IL-6 antibodies in over 90% of patients, improvement in patient's experience), the company is pursuing its clinical development in two indications.

associated with excess IL-6 and low-grade inflammation: inflammatory osteoarthritis of the knee and the prevention of relapses in patients of two rare diseases.

In addition to its clinical level anti-IL-6 product, the company has an R&D pipeline comprising candidates targeting proteins involved in chronic pain, inflammation and oncology, in both human and veterinary health.

Peptinov is supported by renowned experts in osteoarthritis and rare diseases, and its work is gaining increasing visibility, as demonstrated by Peptinov's selection for presentations at OARSI 2024 and EULAR 2024 congresses.

€12m  have been invested in capital since company creation, including €4.67m in 2023. The company is majority-owned by the founders and management, and its shareholders include two institutional investors: the IRCEM pension and health insurance group and FCB holding, which holds a majority stake in the Cégédim group (CGM, Euronext). 
It has also received €2.1m in research grants, €3.3m in research tax credits (Crédit Impôt Recherche) and €1.7m in refundable advances (BPIFrance).

More recently Peptinov has become award winner of the European EIC Accelerator programme (Oct 2023: €8m funding) and of the iDemo call for tender (March 2024: €2.8m funding).